keyword
MENU ▼
Read by QxMD icon Read
search

Lymphoma & leukemia

keyword
https://www.readbyqxmd.com/read/30537151/effects-of-gst-variants-on-the-risk-odds-of-hematological-malignancy-a-meta-analysis
#1
Minjie Li, Meifang Zheng, Hongyun Chen, Haiqing Yu
BACKGROUND: Whether glutathione S-transferases (GST) polymorphisms influence the risk odds of hematological malignancy remains controversial. Therefore, we performed this meta-analysis to better analyze correlations between GST polymorphisms and hematological malignancy. METHODS: Literature retrieve was conducted in PubMed, MEDLINE, and Embase. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated. RESULTS: Sixty-two studies were enrolled for analyses...
December 9, 2018: Journal of Cellular Biochemistry
https://www.readbyqxmd.com/read/30536180/comparison-of-gabexate-mesilate-and-nafamostat-mesilate-for-disseminated-intravascular-coagulation-associated-with-hematological-malignancies
#2
Daisuke Minakata, Shin-Ichiro Fujiwara, Takashi Ikeda, Shin-Ichiro Kawaguchi, Yumiko Toda, Shoko Ito, Shin-Ichi Ochi, Takashi Nagayama, Kiyomi Mashima, Kento Umino, Hirofumi Nakano, Ryoko Yamasaki, Kaoru Morita, Yasufumi Kawasaki, Miyuki Sugimoto, Chihiro Yamamoto, Masahiro Ashizawa, Kaoru Hatano, Kazuya Sato, Iekuni Oh, Ken Ohmine, Kazuo Muroi, Tsukasa Ohmori, Yoshinobu Kanda
We evaluated clinical outcomes of disseminated intravascular coagulation (DIC) in patients with hematological malignancies treated with synthetic protease inhibitors (SPIs) and compared the effects of gabexate mesilate (FOY) and nafamostat mesilate (FUT). We retrospectively examined 127 patients [acute myeloid leukemia (n = 48), acute lymphoblastic leukemia (n = 25), and non-Hodgkin lymphoma (n = 54)] with DIC, who were diagnosed according to Japanese Ministry of Health, Labour and Welfare criteria and treated with SPIs [FOY (n = 55) and FUT (n = 72)] at our hospital from 2006 to 2015...
December 8, 2018: International Journal of Hematology
https://www.readbyqxmd.com/read/30534535/the-notch-pathway-and-its-mutations-in-mature-b-cell-malignancies
#3
REVIEW
Francesca Arruga, Tiziana Vaisitti, Silvia Deaglio
The systematic application of next-generation sequencing to large cohorts of oncologic samples has opened a Pandora's box full of known and novel genetic lesions implicated in different steps of cancer development and progression. Narrowing down to B cell malignancies, many previously unrecognized genes emerged as recurrently mutated. The challenge now is to determine how the mutation in a given gene affects the biology of the disease, paving the way to functional genomics studies. Mutations in NOTCH family members are shared by several disorders of the B series, even if with variable frequencies and mutational patterns...
2018: Frontiers in Oncology
https://www.readbyqxmd.com/read/30530754/ablation-of-mir-146b-in-mice-causes-hematopoietic-malignancy
#4
Takahiro Mitsumura, Yoshiaki Ito, Tomoki Chiba, Takahide Matsushima, Ryota Kurimoto, Yoko Tanaka, Tomomi Kato, Keisuke Uchida, Takashi Ito, Kouhei Yamamoto, Yoshinobu Eishi, Masanobu Kitagawa, Yasunari Miyazaki, Naohiko Inase, Hiroshi Asahara
Excessive and constitutive activation of nuclear factor-κB (NF-κB) leads to abnormal cell proliferation and differentiation, leading to the development of malignant tumors, including lymphoma. MicroRNA 146a (miR-146a) and miR-146b, both of which carry an identical seed sequence, have been shown to contribute to inflammatory diseases and tumors by suppressing the expression of key molecules required for NF-κB activation. However, the functional and physiological differences between miR-146a and miR-146b in disease onset have not been fully elucidated...
December 11, 2018: Blood Advances
https://www.readbyqxmd.com/read/30528964/recent-advances-in-car-t-cell-toxicity-mechanisms-manifestations-and-management
#5
REVIEW
Jennifer N Brudno, James N Kochenderfer
Chimeric antigen receptor (CAR) T-cell therapy is an effective new treatment for hematologic malignancies. Two CAR T-cell products are now approved for clinical use by the U.S. FDA: tisagenlecleucel for pediatric acute lymphoblastic leukemia (ALL) and adult diffuse large B-cell lymphoma subtypes (DLBCL), and axicabtagene ciloleucel for DLBCL. CAR T-cell therapies are being developed for multiple myeloma, and clear evidence of clinical activity has been generated. A barrier to widespread use of CAR T-cell therapy is toxicity, primarily cytokine release syndrome (CRS) and neurologic toxicity...
November 14, 2018: Blood Reviews
https://www.readbyqxmd.com/read/30526160/emerging-cellular-therapies-for-cancer
#6
Sonia Guedan, Marco Ruella, Carl H June
Genetically engineered T cells are powerful new medicines, offering hope for curative responses in patients with cancer. Chimeric antigen receptor (CAR) T cells were recently approved by the US Food and Drug Administration and are poised to enter the practice of medicine for leukemia and lymphoma, demonstrating that engineered immune cells can serve as a powerful new class of cancer therapeutics. The emergence of synthetic biology approaches for cellular engineering provides a broadly expanded set of tools for programming immune cells for enhanced function...
December 10, 2018: Annual Review of Immunology
https://www.readbyqxmd.com/read/30522954/synthesis-and-biological-evaluation-of-novel-1-substituted-3-3-phenoxyprop-1-yn-1-yl-1h-pyrazolo-3-4-d-pyrimidin-4-amines-as-potent-bruton-s-tyrosine-kinase-btk-inhibitors
#7
Nan Zheng, Qun Hao, Kuaile Lin, Jing Pan, Yingxia Li, Weicheng Zhou
A new series of 1-substituted pyrazolopyrimidine derivatives were synthesized as potent BTK inhibitors and they were evaluated by enzyme-based assay and anti-proliferation against multiple B-cell lymphoma cell lines in vitro. Among these compounds, 9h exhibited the highest potency against BTK enzyme, with IC50 value of 4.2 nM. In particular, 8 and 9f performed better inhibition against the proliferation of B lymphoma cell lines DOHH2 and WSU-DLCL2 than the clinical drug ibrutinb. In addition, the test toward the normal PBMC cells showed that 8 possessed low cell cytotoxicity...
November 27, 2018: Bioorganic & Medicinal Chemistry Letters
https://www.readbyqxmd.com/read/30522515/the-risks-of-cancer-development-in-systemic-lupus-erythematosus-sle-patients-a-systematic-review-and-meta-analysis
#8
Lebin Song, Yi Wang, Jiayi Zhang, Ninghong Song, Xiaoyun Xu, Yan Lu
BACKGROUND: Although accumulating data have suggested the development of cancer in systemic lupus erythematosus (SLE) patients, these results remain inconsistent. To examine such a putative association, this analysis reports the association between SLE and the risks of 24 cancer types. METHODS: Online databases PubMed, EMBASE, and Web of Science were searched comprehensively for eligible studies, published up to 15 May 2018. Pooled standardized incidence rates (SIRs) with 95% confidence intervals (CIs) were utilized to reveal their associations...
December 6, 2018: Arthritis Research & Therapy
https://www.readbyqxmd.com/read/30522172/-diagnostic-and-therapeutic-values-of-interphase-fluorescence-in-situ-hybridization-in-b-cell-lymphomas-a-clinicopathologic-analysis-of-604-cases
#9
M Chen, J L Yang, S Zhao, W P Liu, G D Li, Y X Ye, J Q Yan, W Y Zhang
Objective: To investigate the feasibility and value of interphase fluorescence in situ hybridization (FISH) in the pathological diagnosis, differential diagnosis and therapeutic assessment of B-cell lymphomas. Methods: The cohort included 604 cases of B-cell lymphoma which were collected at West China Hospital from May 2010 to December 2016.And all were subjected to interphase FISH using 11 break apart or fusion probes (MYC, bcl-2, bcl-6, IRF4, MYC/IgH, bcl-2/IgH, CCND1/IgH, IgH, API2/MALT1, p53/ATM, and D13S319/CEP12)...
December 8, 2018: Zhonghua Bing Li Xue za Zhi Chinese Journal of Pathology
https://www.readbyqxmd.com/read/30521823/pemphigus-and-hematologic-malignancies-a-population-based-study-of-11-859-patients
#10
Eden Lake
•Hematologic malignancies have been reported sporadically in patients with pemphigus.•In the current study, significant associations were observed between pemphigus and chronic leukemia, multiple myeloma, and non-Hodgkin lymphoma.•Further research is needed to confirm these findings in other cohorts.
December 3, 2018: Journal of the American Academy of Dermatology
https://www.readbyqxmd.com/read/30517310/-the-brazilian-market-for-monoclonal-antibodies-used-in-cancer-treatment
#11
Thaís Jeronimo Vidal, Tatiana Aragão Figueiredo, Vera Lúcia Edais Pepe
Monoclonal antibodies (mABs) have been indicated as an innovative technology for the treatment of some types of cancer, since they are capable of targeting and selectively killing tumor cells. However, the high costs of these therapies raise questions as to the sustainability of access. This study aimed to identify the principal characteristics of monoclonal antibodies used in cancer treatment with active marketing authorization in Brazil as of 2016. This was a descriptive retrospective analysis based on consultation of the Brazilian Health Regulatory Agency (Anvisa) website, in which these mABs were characterized according to the target antigen, type of antibody, year of registration, therapeutic indications, and applicant...
November 29, 2018: Cadernos de Saúde Pública
https://www.readbyqxmd.com/read/30517020/cost-associated-with-hematopoietic-stem-cell-transplantation-a-retrospective-claims-data-analysis-in-germany
#12
Lukas Mayerhoff, Moritz Lehne, Lennart Hickstein, Tayyab Salimullah, Sigurd Prieur, Simu K Thomas, Jie Zhang
AIM: Quantify hematopoietic stem cell transplantation (HSCT) costs in German patients with acute lymphoblastic leukemia (ALL), diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL). METHODS: The primary outcome was direct and indirect costs in patients with ALL/DLBCL/FL who received HSCT between 2010 and 2014. Costs were evaluated two to four quarters before to eight quarters after HSCT. RESULTS: Among 258 patients with HSCT, direct costs were €290,125/patient (pediatric ALL), €246,266/patient (adult ALL), €230,399/patient (DLBCL/FL allogeneic) and €107,457/patient (DLBCL/FL autologous)...
December 5, 2018: Journal of Comparative Effectiveness Research
https://www.readbyqxmd.com/read/30510816/solitary-lytic-bone-metastasis-a-rare-presentation-of-small-lymphocytic-leukemia
#13
Heather Katz, Steven Sagun, Doreen Griswold, Mohamed Alsharedi
Chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) is a hematologic malignancy characterized by an over accumulation of incompetent neoplastic lymphocytes. Bone metastasis in CLL/SLL is very rare. We report a case of a 76-year-old Caucasian female presented with an unresolving pulmonary infiltrate with mediastinal lymphadenopathy concerning for malignancy. Positron emission tomography (PET)/computed tomography (CT) showed an infiltrative mass in the mediastinum with diffuse uptake and a hypermetabolic mass within the left iliac bone...
2018: Case Reports in Hematology
https://www.readbyqxmd.com/read/30504319/richter-transformation-in-the-era-of-novel-agents
#14
REVIEW
Wei Ding
Recent approvals of several oral targeted agents have revolutionized chronic lymphocytic leukemia (CLL) therapy. However, CLL patients continue to progress; particularly, 4% to 20% of previously treated CLL patients undergo transformation into high-grade lymphoma. Richter transformation is defined as a transformation of CLL into aggressive lymphoma, most commonly diffuse large B-cell lymphoma. These patients typically have poor response to traditional chemotherapy used to treat de novo diffuse large B-cell lymphoma and similar or shorter overall survival (median 3-11 months) in the era of novel agents...
November 30, 2018: Hematology—the Education Program of the American Society of Hematology
https://www.readbyqxmd.com/read/30502415/human-oncoviruses-mucocutaneous-manifestations-pathogenesis-therapeutics-and-prevention-part-ii-hepatitis-viruses-human-t-cell-leukemia-viruses-herpesviruses-and-epstein-barr-virus
#15
REVIEW
Uyen Ngoc Mui, Christopher T Haley, Ramya Vangipuram, Stephen K Tyring
In 1964, the first human oncovirus, Epstein-Barr virus (EBV), was identified in Burkitt lymphoma cells. Since then, six other human oncoviruses have been identified: human papillomavirus (HPV), Merkel cell polyomavirus (MCPyV), hepatitis B and C viruses (HBV and HCV), human T-cell lymphotropic virus-1 (HTLV-1), and human herpesvirus-8 (HHV-8). These viruses are causally linked to 12% of all cancers, many of which have mucocutaneous manifestations. Additionally, oncoviruses are associated with many benign mucocutaneous diseases...
November 28, 2018: Journal of the American Academy of Dermatology
https://www.readbyqxmd.com/read/30501725/-characteristics-of-cd180-expression-and-its-diagnostic-value-in-b-cell-chronic-lymphoproliferative-disorders
#16
Jing Wu, Yan Sheng, Jing-Ni Sui, Xiang-Qin Weng
OBJECTIVE: To investigate the charactcristics of CD180 expression and differentiation diagnostic value in B cell chronic lymphoproliferative disorders (B-CLPD) through detecting the mean fluorescence intensity(MFI)of CD180 in different sub types of B-CLPD,using multiparameter flow cytometry (FCM). METHODS: The CD180 MFI of malignant B cells in 178 patients with B-CLPD was detected by FCM. The level of CD180 MFI in various types of B-CLPD was compared to the normal control group...
December 2018: Zhongguo Shi Yan Xue Ye Xue za Zhi
https://www.readbyqxmd.com/read/30500439/patient-reported-outcomes-with-chimeric-antigen-receptor-t-cell-therapy-challenges-and-opportunities
#17
REVIEW
Navneet S Majhail, Rajshekhar Chakraborty, Gunjan L Shah, Betty K Hamilton, Michael Scordo, Surbhi Sidana
Patient-reported outcomes (PROs) are an important tool to assess the impact of a new therapy on symptom burden and health-related quality of life (HRQoL). Chimeric Antigen Receptor-T (CAR-T) cell therapies have been approved for use in relapsed or refractory leukemia and lymphoma based on promising efficacy in clinical trials. However, there is a lack of data on patient-reported toxicity and impact on HRQoL. This review provides an overview of the incorporation of PROs in CAR-T cell therapy and the specific challenges in this context...
November 27, 2018: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/30499908/factors-influencing-do-not-resuscitate-status-in-children-during-last-month-of-life-single-institution-experience
#18
Bilal Moaed, Oz Mordechai, Myriam Weyl Ben-Arush, Sharon Tamir, Ruth Ofir, Sergey Postovsky
BACKGROUND: It is currently expected that about 20% of children with cancer will ultimately die. Writing advanced life directives sufficiently long before the actual death of a child ensues allows both parents and medical staff to develop optimal treatment plans in the best interests of the child. AIM OF THE STUDY: The aim of the study was to evaluate factors that may influence the process of decision-making regarding Do-Not-Resuscitate (DNR) status. METHODS: Retrospective single institution study...
November 28, 2018: Journal of Pediatric Hematology/oncology
https://www.readbyqxmd.com/read/30486601/improving-anti-cancer-potentiality-and-bioavailability-of-gallic-acid-by-designing-polymeric-nanocomposite-formulation
#19
Hanaa H Ahmed, Asmaa F Galal, Aziza B Shalby, Ahmed A Abd-Rabou, Fathy M Mehaya
Objective: In this study, we investigated the in vivo antitumor activity and pharmacokinetic characteristics of encapsulated GA-NC (gallic acid nanocomposite) in normal and hepatocellular carcinoma (HCC)-induced rats. Methods: Rats were distributed into 4 groups; negative control, HCC, gallic acid (GA), and GA-NC. Serum levels of alpha-fetoprotein (AFP), endoglin (ENG), heat shock protein-70 (HSP-70), pro-caspase 3, lipocalin-2 (LCN-2) and β-cell leukemia/lymphoma 2 (Bcl-2) were assayed by ELISA. The pharmacokinetic parameters for GA or GA-NC were determined by means of non-compartmental approach based on the serum– concentration profiles of free GA and GA-NC after oral administration...
November 29, 2018: Asian Pacific Journal of Cancer Prevention: APJCP
https://www.readbyqxmd.com/read/30485531/selenoprotein-s-protects-against-high-glucose-induced-vascular-endothelial-apoptosis-through-the-pkc%C3%AE-ii-jnk-bcl-2-pathway
#20
Shanshan Yu, Xiaoying Liu, Lili Men, Junjie Yao, Qian Xing, Jianling Du
Vascular endothelial apoptosis is closely associated with the pathogenesis and progression of diabetic macrovascular diseases. Selenoprotein S (SelS) participates in the protection of vascular endothelial and smooth muscle cells from oxidative and endoplasmic reticulum stress-induced injury. However, whether SelS can protect vascular endothelium from high glucose (HG)-induced apoptosis and the underlying mechanism remains unclear. The present study preliminarily analyzed aortic endothelial apoptosis and SelS expression in diabetic rats in vivo and the effects of HG on human umbilical vein endothelial cell (HUVEC) apoptosis and SelS expression in vitro...
November 28, 2018: Journal of Cellular Biochemistry
keyword
keyword
165366
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"